

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BioDlink International Company Limited**

**東曜藥業股份有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1875)**

## **VOLUNTARY ANNOUNCEMENT**

This announcement is made by BioDlink International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company has noted the unusual movements in the price and trading volume of the shares of the Company. Having conducted reasonable internal review, the board of directors of the Company (the “**Board**”) confirms that as at the date of this announcement, it is not aware of any undisclosed material adverse developments, operational changes, risk events or any other information that needs to be disclosed to avoid a false market in the Company’s securities, or any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The voluntary general cash offer by WuXi XDC Cayman Inc. (藥明合聯生物技術有限公司\*) (“**WuXi XDC**”) in respect of the shares of the Company was completed in March 2026. The integration of businesses, systems and teams is progressing steadily and in an orderly manner. In May 2026, the Group entered into a conditional framework agreement with WuXi XDC (the “**CDMO Master Services Agreement**”), pursuant to which the Group will provide contract development and manufacturing organisation (“**CDMO**”) services in connection with bioconjugate drugs and their respective components to WuXi XDC for the three financial years ending 31 December 2028, thereby providing a foundation for sustainable business growth. Leveraging WuXi XDC’s established platform, the Company will achieve comprehensive upgrades in quality control capabilities, track record and access to global client resources. The CDMO Master Services Agreement is subject to shareholders’ approval at the upcoming extraordinary general meeting to be held on 11 June 2026. For more details, please refer to the announcement of the Company dated 26 May 2026 and the circular to the shareholders of the Company dated 26 May 2026 (the “**Circular**”). As disclosed in the Circular, the CDMO Master Services Agreement is expected to fully revitalise the Group’s existing production capacity and enhance its capacity utilisation efficiency. The CDMO Master Services Agreement will enable the Group to access and draw upon the WuXi XDC’s established global customer network, supply chain infrastructure, advanced technical know-how, operational best practices and regulatory compliance systems, while contributing its own specialised capabilities in antibody-drug conjugates (“**ADC**”) development and manufacturing. It is expected to promote the overall efficient integration of internal Group resources, unlock the synergy value of the holding platform, and ultimately maximise returns for the Shareholders.

The ADC sector maintains strong growth momentum, as demonstrated by clinical data showcased at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. In particular, multiple next-generation ADCs against novel differentiated targets achieved breakthrough progress toward potential first-in-class innovations. Furthermore, ADC+PD 1 combinations are now approved for first-line treatment, cementing ADCs as essential therapeutic components. Accordingly, the expanding range of validated targets and advancing novel ADC pipelines are driving rising outsourcing demand for CDMO services, laying a solid foundation for the Group's sustainable business expansion. Supported by this industry growth and its leading platform, the Company maintains solid fundamentals and remains confident in the long-term prospects of the business. The Company will continue to press ahead with the post-completion integration, strengthen its core operations and safeguard the interests of the Company and its shareholders.

The Company will make further announcement(s) as and when required to comply with its disclosure requirements under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and/or other applicable laws and regulations.

**Shareholders, holders of other securities and potential investors are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**BioDlink International Company Limited**  
**Dr. Jincal LI**  
*Chairperson*

Hong Kong, 2 June 2026

*As at the date of this announcement, the executive Director is Dr. Jincal Li; the non-executive Director is Mr. Xiaojie Xi; and the independent non-executive Directors are Mr. Xin Fan, Dr. Ulf Grawunder and Dr. Chaohong Hu.*

*\* for identification purposes only*